MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer
Adenocarcinoma of the Pancreas

Interventions: Drug: Bevacizumab
Drug: Erlotinib
Drug: Gemcitabine

First Posted Date: 2006-08-21

Last Posted Date: 2017-05-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 32

Registration Number: NCT00366457

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Evaluation of Hand Assessments in Children With Severe Hand Burns

Not Applicable

Terminated

Conditions: Burns

Interventions: Behavioral: Functional hand tests

First Posted Date: 2006-08-15

Last Posted Date: 2012-03-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 3

Registration Number: NCT00363675

Locations: 🇺🇸
Shriners Hospitals for Children - Boston, Boston, Massachusetts, United States

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer

Phase 2

Completed

Conditions: Biliary Tract Cancer
Gallbladder Adenocarcinoma

Interventions: Drug: Bevacizumab
Drug: Gemcitabine
Drug: Oxaliplatin

First Posted Date: 2006-08-08

Last Posted Date: 2017-02-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 35

Registration Number: NCT00361231

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

SU011248 in Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma
Liver Cancer

Interventions: Drug: SU011248

First Posted Date: 2006-08-08

Last Posted Date: 2014-03-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 34

Registration Number: NCT00361309

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Biological Markers of Response to Treatment in Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: open-label selective serotonin reuptake inhibitor (SSRI)

First Posted Date: 2006-08-08

Last Posted Date: 2018-05-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 72

Registration Number: NCT00361218

SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Carcinoma

First Posted Date: 2006-08-08

Last Posted Date: 2017-02-17

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 6

Registration Number: NCT00361244

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Dietary Supplement: docosahexaenoic acid
Dietary Supplement: eicosapentaenoic acid
Drug: Placebo

First Posted Date: 2006-08-08

Last Posted Date: 2014-07-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 196

Registration Number: NCT00361374

Locations: 🇺🇸
Depression Clinical Research Program, Massachusetts General Hospital, Boston, Massachusetts, United States

Bevacizumab and Radiation Therapy for Sarcomas

Phase 2

Completed

Conditions: Soft Tissue Sarcoma
Fibrosarcoma
Liposarcoma
Synovial Sarcoma
Fibrous Histiocytoma
Leiomyosarcoma

Interventions: Drug: Bevacizumab
Radiation: Radiation Therapy
Procedure: Surgery

First Posted Date: 2006-07-25

Last Posted Date: 2017-05-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT00356031

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting.

Not Applicable

Completed

Conditions: Congestive Heart Failure

Interventions: Other: Drug therapy for HF
Other: NT-proBNP guided HF therapy

First Posted Date: 2006-07-12

Last Posted Date: 2019-03-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 152

Registration Number: NCT00351390

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Letrozole Treatment in Normal and GnRH Deficient Women

Phase 1

Conditions: Healthy Volunteers

Interventions: Drug: Letrozole
Drug: NAL-GLU GnRH antagonist

First Posted Date: 2006-07-12

Last Posted Date: 2017-07-27

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 15

Registration Number: NCT00351416

Locations: 🇺🇸
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy